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ABSTRACT 
Bardet-Biedl Syndrome (BBS) is an autosomal recessive, genetically heterogenous, 
ciliopathic condition, characterized by dystrophic extremities, retinal dystrophy, obesity, 
renal abnormalities and male hypogonadism. It is possible that inheritance of a single 
BBS mutation may predispose to complex diseases such as obesity, hypertension and 
diabetes, particularly as these disorders occur frequently in BBS. To determine the 
incidence of metabolic and renal events 46 BBS cases, 96 heterozygote BBS mutation 
carriers, and 37 relatives without a BBS mutation were studied. Cases have been 
followed prospectively for up to 28 years, but relatives were assessed for the first time. 
The molecular basis of BBS was identified in all families in whom DNA was obtained: 9 
mutations in 6 different BBS genes were discovered in 21 families. Body mass index in 
adult cases was 38 ± 12, in carriers 28 ± 6 and in non carriers 29 ± 3. Hypertension had 
developed in 72% of cases, in 54% of carriers and 49% of non carriers. Median time to 
onset of hypertension treatment was 34, 63 and 67 years respectively. Diabetes had 
developed in 50% of cases, 17% of carriers, and 24% of non carriers, with median time to 
diabetes being 43, 75 years and not achieved respectively. Stage 3 chronic kidney 
disease had developed in 4 7% of cases, 11% of carriers, 15% of non carriers, with 
median age to diagnosis being 58, 86 and 81 years respectively. 
Metabolic and renal events occurred frequently and at an early age in BBS. There were 
no significant differences in the risk of these events comparing carriers of a BBS 
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mutation to non carriers. Inheritance of a BBS mutation does not predispose to obesity, 
diabetes, hypertension or renal impairment. 
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1 Introduction: 
1.1 Newfoundland's Founder Population: 
The Island of Newfoundland is one of the world's richest resources for study of genetic 
disease. Arrythmogenic right ventricular cardiomyopathy, hereditary cancers such as 
colon cancer, polycystic kidney disease, and numerous other inherited conditions all have 
a high prevalence in Canada's easternmost province. Newfoundland's population may be 
useful in the study of autosomal recessive, autosomal dominant and complex genetic 
disease. A high co-efficient of kinship, essentially the marriage of cousins, has resulted 
in a predisposition to some autosomal recessive conditions like Bardet Biedl Syndrome 
[1]. The settling ofNewfoundland has led to several distinct genetic isolates, within 
which autosomal recessive conditions are more likely to arise. Ninety percent of 
Newfoundland's current population has arisen from approximately 30,000 founders [1]. 
Geographic isolation, segregation by religion, and founder effects predispose 
Newfoundlanders to genetic disease. In addition, Newfoundlanders have had large 
families throughout generations, who have settled in or near the core community and 
there has been little in or out migration. Close family connections facilitate the study of 
genetic conditions [ 1]. 
The island ofNewfoundland was settled primarily in response to high demand for cod 
fish in Europe in the late 1700's and early 1800's. The bulk of the settlers who came to 
exploit the rich fishery in Eastern Canada came from two distinct populations. These 
settlers came from Southeast Ireland and Southwest England. Both of these groups were 
fairly homogenous in their homeland origins, and often settled within specific outport 
communities ofNewfoundland that were geographically isolated. The Irish settlers came 
in two major migrations, and the English came in a fairly steady flow for a period of the 
early 1800's and the 1830's [1]. After this rush to settle, the migration essentially 
stopped, and the population growth ofNewfoundland was driven by natural reproduction. 
In the 1980's Newfoundland's population reached its peak at approximately 580,000 
people, of whom an estimated 90% can be traced to the initial20,000-30,000 settlers. 
Geographic isolation of coastal settlements was perpetuated by dependence on the cod 
fishery, lack of roads and by the segregation of the Irish settlers who were mostly 
Catholic from the English settlers who were largely Protestant. Any expansion of these 
isolated communities was primarily due to the division of land amongst descendants of 
original settlers, and settlement of descendents in nearby coves and bays which did little 
to contribute to the genetic diversity of large families [1, 2]. Little has changed over time 
into the modem era. In 1982, 50% ofthe Newfoundland population lived in towns of 
less than 2500, and 41% in towns ofless than 1000 [1, 2]. 
The settlement and expansion ofNewfoundland, coupled with religious segregation, 
close family ties, a high coefficient of kinship, low gross in and out migration has created 
a number of genetic isolates, defined by the coastal geography [1, 2]. None the less, 
Newfoundland is the most generalizable of founder populations to Caucasian 
populations. [3]. 
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1.2 Bardet-Biedl Syndrome: 
Bardet-Biedl syndrome (BBS) is an autosomal recessive disorder characterized 
predominantly by obesity, retinal dystrophy, dystrophic extremities, male 
hypogenitalism, and renal malformations. Secondary features of this syndrome include 
diabetes mellitus, endocrine dysfunction, neurologic abnormalities, learning difficulties, 
and systemic abnormalities in nearly every organ [4] . 
The prevalence ofBBS has been estimated variously as 1 in 160000 (Switzerland) [5,6], 
1 in 150000 in the European population [7], and 1 in 100000 as the global prevalence [8]. 
Newfoundland has a very high prevalence ofBardet-Biedl syndrome, estimated at 1 in 
18000 live births [9], and that figure is only surpassed by the rate seen in Kuwaiti 
Bedouins which is 1 in 13500 [10]. 
1.2.1 Early Descriptions of BBS: 
The Britons, Laurence and Moon first described four mentally retarded siblings with 
obesity and retinal dystrophy in 1866. The three males in the case studies had small 
genitals and walked with an ataxic gait [11]. The syndrome was called Laurence-Moon 
Syndrome. Bardet and Biedl, in 1920, and 1922 respectively, reported similar cases, in 
French and Austrian children, and the patients ofBiedl also had polydactyly [12, 13]. 
After these reports, the conditions Laurence-Moon Syndrome and Bardet Biedl syndrome 
were considered to be expressions of the same condition, called Laurence-Moon-Bardet 
Biedl Syndrome (LMBBS) [14]. Literature reviews performed by Klein and Ammann 
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(1969) and Schachat (1982) suggested that the two conditions were distinct, with LMS 
involving a progressive spasticity and no sign of polydactyly [ 6, 15]. This division was 
widely adopted in the scientific community, with the majority of patients previously 
diagnosed with LMBBS then being given the diagnosis ofBBS. However, more recent 
molecular genetic research has shown that BBS mutations are responsible for phenotypes 
that appear to conform to the LMS diagnosis [9]. Of 46 BBS cases in the Newfoundland 
cohort, two cases met the criteria for LMS. One case, meeting the LMS diagnostic 
criteria, had siblings with BBS who did not meet LMS criteria. All affected individuals 
in this extended family were later shown to have the same BBS5 mutations. The other 
instance of a phenotype consistent with LMS was seen in a family with BBS6 mutations. 
This project is the extension of several years of work on the Newfoundland population of 
Bardet-Biedl syndrome. The project began with ascertainment and assessment of cases 
of BBS through the Canadian National Institute for the Blind. 
1.2.2 Clinical Manifestations of BBS 
Bardet-Biedl syndrome is associated with many deleterious clinical outcomes. BBS has 
manifestations in almost all of the body's organs. The lives ofBBS affected individuals 
are significantly burdened by the syndrome, and their lifespan is often much shorter than 
the average for their population [9]. 
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1.2.2.1 Vision: 
Bardet-Biedl patients have severely impaired vision. The retinal dystrophy found in BBS 
is often classed as a rod-cone dystrophy. Individuals with BBS are frequently registered 
blind in their teens or twenties, and many lose all vision by their twenties or thirties. 
1.2.2.2 External Physical Abnormalities: 
Brachydactyly, syndactyly, and polydactyly of the hands and feet are seen regularly. 
Facial and cranial structure is also frequently affected. Patients show a flat affect in their 
faces and often have narrowing of the skull around the temples. Men with BBS are 
subject to hypogonadism, characterized by small, buried penises and undescended testes 
[4, 7, 9]. Women also may be burdened with sexual structural abnormalities, some 
women having dystrophic vaginas [9]. It is of note that none of the men with BBS in the 
Newfoundland population have fathered a child, women have similarly reduced or 
impaired fecundity; with only two lives birth reported [9]. 
1.2.2.3 Obesity: 
Obesity is one ofthe cardinal manifestations ofBBS. Twenty five percent of the 
Newfoundland BBS population had a Body Mass Index (BMI) higher than 40 [9]. This is 
known as morbid obesity, and is associated with substantial morbidity. 
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1.2.2.4 Endocrine Disease: 
Diabetes and impaired glucose tolerance are very commonly associated with BBS. A 
study from the late 80 s and early 90 s, showed abnormalities in gonadotrophins in 
women, and that reproduction was low [ 4]. 
1.2.2.5 Hypertension: 
BBS patients in Newfoundland are subject to early onset of hypertension (median age 34) 
[9]. 
1.2.2.6 Renal Structure and Function: 
In the Newfoundland BBS population, 100% of patients who underwent a renal 
ultrasound had a structural abnormality [9]. BBS patient kidneys frequently show fetal 
lobulation. Calyceal blunting or clubbing, renal cysts, and some degree of kidney failure 
are all features ofthe syndrome [4, 9, 16]. Depressed renal function in those with BBS 
could predispose to hypertension. 
1.2.2.7 Neurological Disease: 
Traditionally BBS was thought to be associated with mental retardation. However, with 
IQ testing appropriate for those with severe vision loss, only a third had below normal IQ 
[4]. Learning disabilities, however, are common. BBS patients also have a host of other 
neurological deficits. Ataxic gait, poor coordination, abnormal cranial nerve function, 
6 
impaired eye movement, difficulty forming words and sounds are all common [9] . There 
is also an increased prevalence of mental disorders in the BBS population [ 4, 9]. 
1.2.3 Establishment of a Clinical Phenotype for BBS: 
To classify and diagnose BBS a clinical phenotype was defined that took into account the 
cardinal and secondary manifestations ofBBS [9, 17]. This undertaking created a 
concrete list a characteristics and outcomes most associated with BBS. This clinical 
phenotype excluded mental retardation, which was previously listed as a clinical 
manifestation of the syndrome. In recent years, it has been suggested that the lack of 
intellectual stimulation in BBS affected persons contributed to their developmental delay 
[ 4, 9]. Their blank and expressionless faces, caused by poor coordination of facial 
muscles, together with blindness, obesity, and dystrophic extremities also gave the 
impression of retardation. 
Newfoundland Bardet-Biedl syndrome patients were first ascertained through a review of 
the records of the Canadian National Institute of the Blind (CNIB), and subsequently 
through referral by Ophthalmologists or the Newfoundland Provincial Medical Genetics 
program. All patients had complete clinical investigations and detailed medical record 
reviews. Clinical diagnosis of BBS was made by the patient being positive for 4 of the 
cardinal BBS manifestations, or by being a sibling, with 3 cardinal manifestations, of a 
positively identified BBS patient. The description of the clinical phenotype of the 
Newfoundland BBS cohort was derived initially from the work of Green et al, Harnett et 
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al, and O'Dea et al. [4, 16, 18] . More recently, Moore et al. performed a detailed 
assessment of all available BBS cases in Newfoundland in 2005 [9]. 
1.3 BBS Molecular Genetics And Genotypes: 
Since 1995, Newfoundland families have participated in research to identify the genes 
responsible for BBS. Similar studies of Bedouin BBS families as well as cohorts of BBS 
patients particularly in the United States, Great Britain, and France, have contributed to 
the elucidation of the BBS genes. There are now 12 confirmed BBS genes, BBSJ2 having 
recently been discovered [19]. Two major genes, BBSJ and BBSJ 0, each account for 
~20% ofthe mutational load in families of European descent, whereas ten other genes 
each account for approximately 5%, and some of these were found mutated in only a few 
families or even a single family (the latter in the case of BBSJJ) [19, 20]. The 12 known 
BBS genes account for ~ 70% of affected families, suggesting that additional BBS genes, 
for the remaining 30% remain to be identified. A further complication is the finding that, 
in some cases, inheritance departs from classic autosomal recessive inheritance and may 
involve three mutated alleles in two genes, defined as oligogenic inheritance. It is also 
possible that severity can be modulated by an allele of a modifier gene [19, 21]. 
1.3.1 BBSl: 
Mutations in BBSJ are the most common cause of BBS, and account for approximately 
20% ofthe cases world wide [21, 22]. The gene's chromosomal locus is 11ql3 (23]. 
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BBSJ because of mutations that result in dysfunction in sensory capabilities of the 
ciliated cells [23, 24]. The BBSJ mutation in Newfoundland families is M390R. 
1.3.2 BBS2: 
Mutations in BBS2 account for 8% of BBS cases [21]. Like BBSJ , mutations in BBS2 
result in dysfunction of cellular sensory machinery. The chromosomal locus for BBS2 is 
16q21 [23, 25] . BBS2 mutations are thought to have negative effects in regulation of 
development and growth, which may result in the failure of BBS2 cases to develop fully 
at early stages of growth. Mice with BBS2 mutations display obesity, retinal 
degeneration, renal cysts, male infertility, and olfactory deficiencies [23, 26] . The BBS2 
mutation identified in Newfoundland families is Y24X. 
1.3.3 BBS3: 
BBS3 accounts for a small proportion (0.5%) of world wide BBS cases [21] . The BBS3 
protein product is also known as ADP-ribosylation factor-like protein 6 and its gene is 
found at chromosome location 3p12-q13 [23]. This intracellular protein is responsible for 
a series of molecular signals in the cell via the GTP and the RAS proteins, which are key 
to intracellular trafficking [26, 27]. BBS3 mutations result in changes in amino acid 
residues near the GTP binding site and are likely to prevent GTP binding and therefore 
signal conduction [27]. The mutation identified in Newfoundland is G 169A. 
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1.3.4 BBS4: 
This gene contributes to less than three percent of BBS cases [28]. BBS4 may be an 
adaptor protein that facilitates the loading of cargo onto the dynein-dynactin molecular 
motor in preparation for microtubule-dependent intracellular transport in the cilium or the 
cytosol (figure 1) [29]. Mutations in BBS 4 have been linked with impaired olfaction. 
The gene' s chromosomal locus is 15q22.3-q23 [30]. Mutations in BBS4 in mice led to 
obesity, retinal degeneration, sperm defects, olfactory deficiencies and improperly 
formed olfaction structures [31 , 3 2] . BBS4 mutations have not been identified in 
Newfoundland. 
1.3.5 BBSS: 
Like BBS3, mutations in BBS5, also account for about 0.5% ofBBS cases [21]. 
Localization of the BBS5 protein to basal bodies suggests that it is involved in ciliary 
function (figure 1). In C. elegans, BBS5 silencing results in an unciliated model ofthe 
species. BBS 5 is located at 2q31 and the mutation seen in the Newfoundland BBS5 
families is IVS6+ 3A>G 
1.3.6 BBS6: 
Mutations in the BBS6 gene are thought to be the cause of 5% of BBS cases. However, 
this mutation is much more common in Newfoundland [21]. The BBS6 gene is known as 
MKKS/BBS6 and is located at locus- 20p12. BBS6 is proposed to be an atypical 
member of the superfamily of type II chaperonins, which are mediators for the proper 
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folding of proteins [21, 3 3]. BBS6 may code for a chaperonin which is thought to be key 
in proper mechanoreception and photoreception [34]. Defective BBS6 protein has been 
found in models that have cytokinesis defects, and in mice that are obese, have retinal 
degeneration, sperm flagellation defects and olfactory deficiencies [29, 35]. There are 
three BBS6 mutations seen in the Newfoundland families, F94fsX103 , D143fsX157, and 
L227P. 
1.3.7 BBS7: 
Mutations in BBS7 account for~ 1.5% of cases world wide [21]. BBS7 is required for the 
normal localization/motility of the intraflagellar trafficking (1FT) proteins, and group of 
proteins required for complex shuttling of other proteins along the cilia (figure 1) [26], 
and dysfunction of the protein has been shown to cause ciliary defects and improper 1FT 
in C. Elegans models [36]. The BBS7 gene is located at 4q27. No Newfoundland 
families have been identified with a BBS7 mutation. 
1.3.8 BBS8: 
Mutations in BBS8 account for ~ 1% of BBS cases worldwide [21]. The BBS8 gene is 
located at chromosome 14q32.1. It has been proposed that BBS8 protein, known as 
Tetratricopeptide repeat protein 8 (TTC 8), is required for the normal 
localization/motility of the 1FT proteins [36]. BBS8 protein is associated with centriolar 
structures, ciliary structures, and interacts with a protein that is likely involved in basal 
body function (figure 1) [24, 37]. There are no BBS 8 mutations in Newfoundland. 
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BBS 1-8 proteins all have some similar putative effects. They influence the structure and 
function of Kupffers vesicle, left/right differentiation and mutations in their BBS genes 
have been shown to result in degenerated cilia and delayed intra cellular transport. This 
is explained by defects in the cilia dependant intraflagellar transport chain (figure 1) [20, 
38]. 
1.3.9 BBS9: 
Parathyroid hormone-responsive gene B1 (Bl) , located at chromosome 7p14, was found 
to be a novel BBS gene (BBS9), supported by the identification of homozygous mutations 
in BBS patients [39]. Little is known about the function of this protein. In BBS9 null 
mice, protein B 1 is down regulated in the retina, and this could result in suboptimal 
vision [39]. There are no known Newfoundland BBS9 cases. 
1.3.10 BBSlO: 
20% of BBS cases have mutations in BBSJ 0 [ 40]. Like BBS6, this gene is proposed to 
code for a protein that is an atypical member of the superfamily of type II chaperonins 
[34] . Chaperonins ensure that proteins are folded properly and may impact ciliary protein 
folding and function. The BBS 10 protein may be an active hydrolytic enzyme. 
Suppressing BBS 10 function in zebrafish models causes severe developmental 
irregularities [ 40]. The BBSI 0 gene is located at 12q21.1, and the mutations in BBSI 0 
observed in Newfoundland are C91fsX95 and F198 Del/199 Del. 
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1.3.11 BBSll: 
The protein product of BBSJJ is also known as "tripartite motif protein 32" (TRIM32). It 
is thought to be an ubiquitin ligase, involved in protein turnover by identifying proteins 
for disintegration by "tagging" them with ubiquitin [20]. This is proposed to cause BBS 
by acting on other BBS proteins either directly or indirectly. Mutations in the zebrafish 
model of the BBSJJ gene cause disruption of the ciliated organ, Kuppfer' s vesicle and 
delayed intracellular transport. Mutations of BBSJJ were seen in a single 
consanguineous Bedouin family [20]. The BBSJJ gene is located at 9q31-q34.1. No 
BBSJJ mutations have been identified in Newfoundland. 
1.3.12 BBS 12: 
Like BBS6 and BBSJ 0, the BBS12 gene encodes a protein which is an atypical member of 
the superfamily of type II chaperonins [19, 34, 40]. Mutations in the BBSJ2 gene are 
seen in 5% of BBS families [19]. This gene is found at chromosomal location 4q27. No 
BBS 12 mutations have been identified in Newfoundland. 
Figure 1 is a schematic of the respective roles of several of the aforementioned BBS 
proteins. The figure displays the localization of the various BBS proteins around the cilia 
and basal body, further establishing BBS and a ciliopathy, and indicates that the BBS 
proteins are critical in the maintenance of proper functioning cilia. 
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Figure 1: The Putative Role of BBS Proteins 
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The Cause ofBBS: 
Figure one amalgamates data accrued from several organisms and thus represents an 
idealized cell system. All BBS proteins have been placed in the transition zone (basal 
body), centrosome, and/or ciliary axoneme. There is additional evidence for the role of 
BBS7 and BBS8 in facilitating the selective assembly of intraflagellar transport (1FT) 
proteins into 1FT particles. Knock-down of either BBS7 or BBS8 (only BBS7 is 
illustrated) results in diminished levels ofCHE-11 and OSM-5 (polaris) in the ciliary 
axoneme, culminating in shortening. BBS4 through its direct interaction with the 
p150glued subunit of dynactin probably behaves as an adapter assisting the loading of 
cargo (such as PCM-1) onto the 1FT particles and subsequent transport to the centriolar 
satellites (in the centrosome and the basal body). Given that the primary structure of 
BBS6 is similar to the group II chaperonins, we may speculate that its role is to process 
proteins prior to 1FT assembly and loading, as well as microtubule-dependent membrane 
trafficking [26]. 
This Diagram and the above passage of text appear courtesy of (www .genetests.org) 
and copyright belongs to the University of Washington and Children's Health 
System, Seattle. 
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1.4 Molecular Genetics of Ciliopathies: 
1.4.1 BBS "Spectrum" Disorders: 
There are several conditions that have a distinct likeness to Bardet-Biedl syndrome. 
Exploration ofthese conditions may prove useful in the study ofBBS. 
1.4.1.1 McKusick-Kaufman Syndrome (MKKS): 
MKKSIBBS6 mutation is also associated with MKKS. MKKS was first identified as the 
gene for McKusick-Kaufman syndrome (MMKS) and mutations of the same gene (BBS6) 
can cause BBS. MKKS shares clinical manifestations with BBS, including post-axial 
polydactyly, congenital heart disease and hydrometrocolpos- a congenital abnormality of 
the vagina. BBS may be mistaken for MKKS in infancy or early childhood prior to the 
recognition of other clinical manifestations of BBS, particularly retinal dystrophy which 
is not present in MKKS [26]. 
1.4.1.2 Alstrom Syndrome: 
Rod-Cone dystrophy, obesity, insulin resistance, and physical developmental delay are 
seen in both BBS and in Alstrom Syndrome (AS). However, Alstrom syndrome differs 
in the fact that cognition is generally unimpaired. There is also an absence of 
polydactyly, the presence of progressive hearing loss, and dilated cardiomyopathy, 
neither of the latter two being usually observed in BBS. AS is also transmitted through 
recessive inheritance [26]. 
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1.4.1.3 Biemond 2 Syndrome: 
Mental retardation, hydrocephalus, facial dystosis, hypogonadism, polydactyly, obesity 
and coloboma (holes in the structures of the eye), are all major manifestations of this 
condition. BBS shares some of these manifestations. However, little is known about the 
genetic basis of this condition. 
1.4.2 Oligogenic Inheritance of BBS: 
BBS was initially modeled as a purely recessive trait and the syndrome typically 
segregates in families as a classic autosomal recessive trait. Recent data suggests an 
oligogenic mode of disease transmission in which mutations at different BBS loci may 
interact genetically to cause and/or modify the phenotype [21]. Significant genetic 
heterogeneity and clinical variability in BBS suggest that a second site of genetic 
modification is possible [21]. The second site mutations could alter the penetrance or 
expression of the first mutations, resulting in variable severity of the condition [21, 41]. 
In a few cases, it has been proposed that three mutations at two gene loci may be required 
for BBS expression. This would be the first example of trialle1ic inheritance described in 
humans [ 42]. The BBS2 and BBS6 genes appear to be the most frequently involved in 
triallelic inheritance, however, it has also been stated that the BBS8 gene is the only one 
ofthe 12 BBS genes that does not actually participate in this phenomenon [21]. 
It is difficult to determine the extent to which triallelism is present in BBS but it is 
estimated to be a small percentage of all BBS [26]. 
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1.4.3 Molecular Biology of BBS: 
BBS is caused by mutations that cause dysfunction of basal body and ciliary proteins. 
Thus BBS is a ciliopathy. Research on such conditions is ongoing in a wide spectrum of 
diseases such as BBS, Polycystic Kidney disease, Alstrom Syndrome, Meckel Syndrome, 
Joubert Syndrome and many others [19]. Research of this type has recently come into 
vogue after experimental procedures on flagellated C. Elegans and Chlamydomonas 
indicated that mutations in cilia related genes caused abnormalities. It was suggested that 
the BBS phenotype is the result of ciliary defects at the early stages of fetal development 
[24, 29, 31 , 33, 43]. Properly functioning cilia are of critical importance for proper 
development of many organs, and improper function at later embryonic stages could lead 
to widespread organ disorder as seen in BBS and other ciliopathies. 
1.4.4 Cilia and Flagella: 
Cilia and flagella are microtubule-filled, cellular extensions whose enclosing membrane 
is continuous with the cell plasma membrane. Although cilia and flagella are identical in 
structure and composition, the two names were originally coined to indicate distinctive 
patterns of movement and are still used. A motile cilium contains nine sets of doublet 
microtubules arranged in the form of a hollow cylinder that surrounds a central pair of 
single microtubules [44] . The internal structure of the cilia provides ATP-hydrolysis 
driven mechanical movement that causes the movement ofthe motile cilia. All of these 
microtubules and their associated proteins together form the axoneme, the core of the 
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cilia. Non-motile cilia have few microtubules or a different alignment of the outer 
microtubules and this less advanced structure does not allow for movement [ 44-46]. 
One fascinating feature of cilia and flagella is that the basal body, which templates the 
assembly of their axonemes, contains the same organelle, the centriole, in man and higher 
life, and is also the defining element of another microtubule-related organelle, the 
centrosome [44]. Remarkably, cilia are conserved across many phyla. Centrosomes, 
which contain a pair of centrioles, are the organizing centers for cytoplasmic 
microtubules in the interphase cell and for the spindle microtubules in mitotic cells. The 
centriole and centrosomes are key in the division of mitotic cells, and therefore key in the 
propagation, growth and maintenance of human cells. This creates an interesting link 
between the cilia related defects discussed here and the over proliferation of cells that 
seem to be present in the cystic kidney and the cystic pancreas[44] . Cilia are recognized 
as being chiefly important as mechanoreceptors in kidney epithelium, in the 
photoreceptors of the retina, and in planar cell polarity required for embryonic 
development [19, 24, 29, 41]. 
1.4.5 BBS is a Ciliopathy: 
BBS proteins (BBS 1-8) have been shown to localize to primary cilia in model organisms 
such as C. Elegans and Chlamydamonas. The proteins are likely to be involved in 
intraflagellar transport (IFT)- which moves proteins onto the cilia, ADP rybosylation, and 
chaperonin activity. As many BBS orthologues localise specifically to the organisational 
center of the microtubules, the centrosome and the basal body (which is required for clilia 
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formation), it is quite likely that these proteins could be involved in ciliogenesis, cilia 
maintenance, the 1FT, and/or microtubule dependent intracellular transport [24, 33, 43, 
4 7, 48]. Recent studies have led to a much fuller appreciation of the fact that not only do 
cilia act in sensory roles at critical stages in embryonic development, but their sensory 
roles are essential for the normal functioning of many tissues [ 44]. Defects in these 
proteins have been shown to cause abnormal ciliogenesis. These ciliary defects in critical 
epithelial cells, such as those of the kidney, liver, pancreas, and other areas, may well 
predispose to conditions such as renal cysts, pancreatic cysts, retinal dystrophy and more 
complex manifestations including obesity, hypertension, and diabetes [44, 45]. 
Discovery of new cilia related genes that cause human disease came from studies on the 
mechanism of assembly of the organelles. However, there is a need for further research 
to continue to develop these hypotheses [ 44]. 
The BBS phenotype is consistent with the hypothesis put forward by Ansley (2003) that 
suggests that the vision related manifestations of BBS can be explained by a ciliary defect 
[24]. Dysfunction of the nodal cilium causes reduced protein transport across certain 
photoreceptors in the eye, which then results in retinal dystrophy. Ansley also suggested 
that renal conditions ofBBS had a similar etiology. He proposed that failure of 
mechanosensation at the primary cilium of renal tubular cells causes another related 
condition, cystic kidney disease [24]. Mouse models of polycystic kidney disease 
support this condition being a ciliopathy [24]. Ansley's proposal was that a link between 
ciliary dysfunction and cellular response was at the heart ofthe pathology ofBBS. 
20 
1.4.6 BBS Gene Defects Impact Later Stages of Organ Differentiation: 
It is proposed that the effects of BBS gene defects occur in neurulation and gastrulation 
during the later development of the embryo [29, 49]. Neurulation is the period of early 
fetal development when the rudimentary nervous system is formed. This process creates 
the neural tube, which gives rise to the central nervous system and creates the neural 
crest, which migrates away from the dorsal surface of the neural tube, and differentiates 
into a diverse set of cell types [50]. Gastrulation 'is the developmental phase in which the 
three major layers of human tissue are formed. These germ layers later form into the 
organs of the body. Also during this phase, the primitive body plan is established. 
Essentially these two developmental processes are mediated by cilia, via 
mechanoreception between cells. Current work by Mykytyn et al. has suggested that 
BBS proteins serve as mediators for communication and/or intracellular transport 
between the cilium and the interior of the cell, and suggests that a breakdown in this 
communication may cause the BBS phenotype, with incompletely developed organs [48]. 
The outward appearance of BBS seems to also give this hypothesis weight, as BBS cases 
present with organs that do not appear to be fully developed; including lobulated kidneys 
and poly- and brachydactyly [9]. Incomplete formation of organs at the critical stages of 
neurulation and gastrulation could lead to endocrine dysfunction, organ malformation, 
situs-inversus and other problems associated with BBS. Failure ofthe embryo to 
differentiate properly is suspected to be the cause ofthe cardinal manifestations ofBBS. 
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1.5 Metabolic and Renal Conditions: Diabetes, Obesity, Chronic Renal 
Failure and Hypertension are Prevalent and Costly: 
BBS is associated with obesity, hypertension, diabetes, and chronic renal failure. These 
are common conditions in Canadian society today and are detrimental to health. Further 
study of the mechanisms and mode of inheritance of these conditions is vital to reducing 
the large direct costs of treatment and burden of illness. 
1.5.1 Obesity: 
Obesity is a morbid state which indirectly and directly cost Canadians $4.3 billion in 
2001 [51]. Between 1970-1972 and 1998, the proportion of Canadian adults considered 
overweight or obese increased from 40.0% to 50.7% [51]. 
1.5.2 Diabetes: 
Diabetes is a condition in Canada that has achieved epidemic proportions. 2007 
estimates are that over 2 million Canadians suffer from diabetes [52]. Diabetes is a 
contributing factor in the deaths of approximately 41,500 Canadians each year. Diabetes 
and its complications cost the Canadian healthcare system 13.2 billion dollars per year 
[52]. 
1.5.3 Hypertension: 
An estimated 20% of Canadians are hypertensive [53]. This condition is the single 
largest predictor of heart disease in North America [54]. Seventy three percent of 
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hypertensive patients are under the age of 65, and the condition is associated with a 
massive burden of illness in North American society (54] . 
1.5.4 Chronic Renal Failure: 
While a very small percentage of Canadians have end stage renal disease (0.1 %), chronic 
renal failure represents a great financial burden to Canada: 1.3 billion dollars of direct 
medical costs and 1.9 billion dollars when mortality and morbidity indirect costs are 
considered [55]. 
1.6 Etiology of Metabolic and Renal Diseases in BBS: 
Diabetes, hypertension, chronic renal failure, and obesity are all expressions of the BBS 
phenotype [9]. New studies on BBS raise the possibility that cilia play roles in energy 
metabolism, blood glucose homeostasis, and regulation of blood pressure [ 44, 45]. 
1.6.1 Renal Failure: 
Cilia have long been observed on kidney epithelium, and are suggested to play a major 
role in the proper function of nephrons. It is suggested that ciliary dysfunction in the 
kidney can lead to a number of defects including cysts, calyceal clubbing and tubular 
defects [ 44, 45]. In humans ciliary dysfunction is usually the cause of cystic kidney 
diseases [44, 56]. The kidney epithelial cilia function in a mechanosensory system that 
monitors and responds to fluid flow over the surface of the renal epithelial cells [44, 46, 
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57]. Thus, in normal kidneys, the renal cilia are sensory transducers in a cilium-
generated signaling pathway. 
Cilia dysfunction caused by malfunctioning BBS proteins may also be involved in early 
embryonic development of the nephron or in maintenance of its normal tubular structure. 
Thus, in the embryo, the BBS genes might regulate nephron morphogenesis. 
1.6.2 Hypertension: 
Elevated blood pressure has a hereditary component [44]. The etiology of hypertension 
in BBS is likely to be complex. Predisposing factors include primary renal disease, 
diabetes mellitus and obesity, which occur frequently in BBS. Furthermore, 
abnormalities in intracellular calcium signaling in vascular cells in polycystic kidney 
disease may predispose to hypertension [58]. It is possible that inheritance of a BBS 
mutation may predispose to hypertension. 
1.6.3 Diabetes: 
Cilia have been identified in the exocrine, endocrine, and ductal cells of the pancreas for 
many years [45]. The cilia in the epithelium of the pancreas are thought to be primary, 
non-motile, cilia and function as mechanoreceptors and chemoreceptors. It is currently 
thought that these cells are responsible for regulating fluid flow and ion transport, or 
pressure sensation in the endocrine ducts of the pancreas. Dysfunctional cilia, like those 
affected by mutant BBS proteins, improperly sense flow of fluid produced in the 
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pancreas. Ciliary defects in mice lead to ascinar cell atrophy and duct hyperplasia in the 
pancreas, and compromised glucose homeostatic maintenance [45] . Evidence linking 
diabetes and insulin resistance has been shown in another model of recessively inherited 
ciliopathy, namely Alstrom Syndrome. Hearn et al. indicated that ALMS 1, the protein 
product responsible for Alstrom syndrome, a syndrome similar to BBS, affected the 
function and appearance of cilia in a similar manner to BBS, and caused diabetes and 
insulin resistance [43, 59]. BBS patients are prone to type 2 diabetes and have high 
insulin levels [9]. It is likely that both obesity and primary pancreatic disease contribute 
to insulin resistance. 
1.6.4 Obesity: 
It is not fully understood how defective cilia may lead to obesity; however, one theory is 
that ciliary receptors are necessary for regulating food intake and overall energy 
metabolism. Several cells in humans have known extracellular receptors that are also 
present on cilia. For example, Integrins, cell surface receptors that mediate signaling 
inside the cell, have been localized to the primary cilium of certain cells, where they are 
proposed to influence intracellular Ca2+ levels in a flow-independent mechanism [60]. 
Furthermore, somatostatin receptor 31 02 and the serotonin receptor 5-Ht61 03 are 
localized to neuronal cilia in the brain [ 44]. This establishes a link that suggests that 
other receptors, possibly those involved in the sensation of fullness are found on cilia or 
are cilia dependant. These cilia dwelling receptors could be involved in regulating food 
intake and overall energy metabolism. In fact, many brain neuronal cells that are 
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responsive to the weight-regulating protein Leptin display somatostatin 3 receptors on 
their neuronal cilia [61] . Insensitivity could well cause a decreased sensation of satiety 
and may result in habitual overeating, leading to obesity. These theories suggest that 
BBS obesity could come from overeating because the patients simply do not ever feel 
'full'. 
Recent research in mice suggests that elements of Leptin driven appetite regulatory 
pathway require cilia [ 44]. Hedgehog pathway proteins are a family of secreted signaling 
molecules paramount for inductive cell interactions in embryos. Huangfu reported that 
the Hedgehog signaling pathway was disrupted in mouse embryos with lesions in 
kinesin-11 and two 1FT particle proteins [49]. It is possible that these 1FT machinery 
proteins play a non-ciliary role in the pathway, but one explanation for the results is that 
Hedgehog pathway proteins require cilia for their function [ 49]. This research indicates 
that these hedgehog proteins rely on proper ciliary function to properly differentiate 
tissues and organs in embryonic development and that proper function of Leptin and its 
pathway are dependant on properly functioning cilia. This further substantiates a 
potential correlation between BBS and obesity. 
It is also possible that improper type II chaperonin development, resulting from mutations 
of several BBS genes (BBS6, BBSJ 0, and BBS12) may well be responsible for the 
improper folding of the obesity protein, Leptin [44] . Improperly folded Leptin may not 
correctly sit in its receptor site, and therefore could cause insensitivity to Leptin. 
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Cilia have been observed in the fat storing cells of the liver, and also in the thyroid gland 
and adrenal glands [44]. Dysfunction of the former would lead to improper distribution 
and storage of fat, and the latter may lead to improper regulation of thermogenesis and 
metabolic rate, leading to a predisposition to obesity through sluggishness, 
hypothyroidism, or insensitivity to Leptin. 
1.7 BBS Mutation Carriers may be at Risk: 
Carriers of BBS have one wild type allele as well as one mutated allele. It is proposed 
that being a heterozygous carrier of a BBS mutation may predispose carriers to some of 
the clinical manifestations ofBBS. Qian et al. have shown in polycystic kidney disease 
mice that carrying a single mutant allele led to a variety of altered homeostatic chemical 
levels. It was suggested that increased intracellular calcium accumulations in these 
models could predispose carriers to hypertension [58]. It is possible that this 
phenomenon that had occurred in polycystic kidney disease mice could manifest in the 
carriers of BBS mutations. Beales et al. determined that there was a significant increase 
in renal cancers and malformations in the parents of BBS children. There were similar 
findings in their unaffected siblings, showing a increased risk of kidney problems of 
seventeen and twenty fold respectively [8]. However, others have recently discovered 
contradictory evidence that suggests that there is no link between BBS heterozygosity 
and an increased prevalence of renal cancers. [62]. 
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In recessive conditions associated with cancer or diabetes, some disease manifestations in 
heterozygote carriers have been suggested [8, 63]. Carriers of an autosomal recessive 
syndrome, Ataxia-Telangiectasa, may have a 3 to 4 fold increased risk of developing 
cancers [63]. 
Specific to BBS, obesity, renal disease, diabetes mellitus and hypertension have been 
identified as risks to carriers by Croft et al. [64, 65]. In 1990, Croft and Swift obtained 
hospital records and personal questionnaires in a single BBS family in which they 
discovered that heterozygous carriers for BBS were at substantial risk of renal disease, 
diabetes mellitus, and hypertension. Renal disease was implicated in the death of 3 of the 
proband' s first-degree relatives, and affected one other. Five ofthe proband ' s first-
degree relatives were diabetic, and 5 of the proband's first degree relatives were 
hypertensive. Four of the five first-degree relatives were also classified as obese. 
In 1995 Croft again examined the carriers of Bardet-Biedl Syndrome mutations, assessing 
records and questionnaires on thirty-four parents ofBBS cases, who were obligate 
heterozygotes. Fathers ofBBS children were predominantly overweight. In fact Croft 
showed 26.7% ofBBS fathers to be "severely overweight" (BMI exceeding 31.2). This 
was a 3-fold increase above the 8.9% United States national average taken from the 
NHANES II study [66]. 
Stoetzel et al. in 2007 studied the three BBS proteins corresponding to BBS6, 10 and 12 
in wild type zebrafish. They suppressed each BBS protein individually, 6 and 10 
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together, 6 and 12 together, 10 and 12 together, and all three together. They found 
evidence that the proportion of improperly developed fetuses was dependant on the sum 
effect ofthe suppression of the BBS proteins. These findings suggest that there is a 
"dose dependant" effect to BBS 12, 10, and 6, which also suggests that carrying a mutant 
allele for BBS could lead to clinical BBS manifestations. 
These aforementioned studies do suggest a link between being a carrier of BBS mutations 
and predisposition to the clinical outcomes associated with BBS. However, the clinical 
studies are based only on single families or small sample sizes, and are not properly 
controlled. In addition, the animal studies may not extrapolate to humans. 
1.8 Clinical Epidemiology of BBS in Newfoundland: 
The research published by Harnett et al, Green et al, O'Dea et al provided the initial 
clinical information on BBS in the Newfoundland population [ 4, 9, 16, 18]. Moore et al. 
extended the BBS phenotype, determined if BBS and LMS were the same disorder, 
described the genetic epidemiology of BBS, and determined whether there were 
genotype/phenotype correlations for BBS. These reports established wide spread 
systemic manifestations observed across the BBS cohort, irrespective of genotype and 
included substantial endocrine and renal disease [9]. 
To assess phenotype and outcomes for the BBS cases, Moore et al. evaluated 38 of the 46 
BBS patients in clinic, and reviewed the medical charts of all 46 patients. Anthropometric 
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measures were taken ofhead, face, ears, hands, feet, and ofthe genitals. Dysmorphic 
features were compared to norms created by Hall et al. 1995, and scored by clinical 
geneticists [67]. A neurologist examined 7 patients and 19 patients were assessed on 
standardized and diadochokinetic speech tests. Psychiatric evaluation and verbal IQ 
scores were obtained. Laboratory measures of blood urea, creatinine and random glucose 
were determined on whole blood drawn from the subjects. Renal ultrasound scans were 
performed to assess structural abnormalities. 
Green et al. [4] established that retinal dystrophy leading to blindness, dystrophic 
extremities, obesity, renal abnormalities, and genital and reproductive abnormalities were 
the cardinal manifestations ofBBS, and that diabetes mellitus, hypertension, and renal 
failure occurred frequently. Moore et al [9] extended the phenotype to neurological 
abnormalities, speech disorders, psychiatric abnormalities, gallstone disease, colonic 
disorders, asthma, congenital heart disease, other disorders such as epilepsy/thyroid 
disease, and early death. There were no significant differences between genotypes for 
any of these morbidities. 
1.9 Relevance of Proposed Research: 
Bardet-Biedl Syndrome cases have increased incidence of four major conditions common 
in the community: obesity, hypertension, diabetes and chronic renal failure [4, 9, 16, 18, 
27]. Our research provides more precise estimates of risk because of the long prospective 
follow up of cases. What is not established, is the risk of obesity, hypertension, diabetes, 
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and chronic renal failure in first degree and other relatives who carry a BBS mutation. 
This investigation will test the hypothesis that there is greater risk of these morbid events 
in carriers of BBS mutations as compared to their relatives who do not carry a BBS 
mutation. 
For relatives of those with BBS, it is important that they know if they may be predisposed 
to BBS related morbidities. Given the case rate ofBBS in the Newfoundland population, 
and the likelihood that many of the BBS alleles occur in other members of the population 
it is possible to hypothesize that haploinsufficiency (the state of an organism having only 
a single normal copy of a particular gene) of a BBS protein may contribute to a high rate 
of chronic diseases in the Newfoundland population [27]. This research can also 
contribute to the investigation of the genetic nature of obesity, hypertension, diabetes, 
and chronic renal impairment. 
This is important because the ciliary I basal body I centrosome cellular apparatus is 
complex and dependant on the normal function of multiple proteins. Consequently many 
mutations in the genes controlling this function may occur in the community. 
1.9.1 Institutions: 
This study was performed under the auspices of the Patient Research Center, at Memorial 
University, StJohn's, Newfoundland and was approved by the Human Investigation 
Committee of the Faculty of Medicine; Memorial University. The work was sponsored 
by the Janeway Foundation, and Genome Canada. 
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1.9.2 Objectives of this Study: 
This study characterizes the risk of diabetes, hypertension, chronic renal failure, and 
obesity in the Newfoundland BBS carriers by comparing them to other relatives of BBS 
cases who do not have a BBS mutation. This is the first study of its type in this 
population. 
Objectives: 
1) To describe the incidence of endocrine and renal events in a large group of 
BBS cases followed for 28 years. 
2) To characterize the risk of metabolic and renal conditions in the carriers of 
BBS mutations. 
3) To determine the relative risk of these events in BBS cases and in carriers 
of BBS mutations based on their BBS genotype. 
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2 Methods: 
2.1 Recruitment of Cases: 
The cases of BBS in Newfoundland have been extensively studied since the initial 
recruitment of patients to the study in 1983-1985 through the Canadian National Institute 
for the Blind, and ongoing referrals from Ophthalmologists and the Provincial Medical 
Genetics program. Protocol driven assessments have taken place in 1988 [16], [4], 1993 
[18] and in 2001 [9]. 
A fourth assessment of the cases was performed in 2008. At this time medical charts of 
the BBS cases were reviewed, blood pressure was measured, and blood urea, serum 
creatinine, random glucose, and Hemoglobin Ale tests were performed. 
The current BBS case cohort consists of 46 individuals (26 males and 20 females) from 
26 families. Consanguinity was documented in 27% of families (7 /26) and suspected in 
another 15% ( 4/26). 
2.2 Recruitment of relatives: 
Twenty-one of 26 families participated in the gene discovery research program, of whom 
20 families participated in the current study (Fig 2). Participants included siblings and 
parents of cases, together with some sibships of parents who requested to enroll in the 
study. Of 138 first degree relatives of cases, 78 participated in the study, 23 were dead 
and 37 did not participate. Of 107 siblings of parents, 55 participated, 24 were dead and 
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28 did not participate. Thus of 198 living eligible relatives 67% (N=133) participated in 
the study. DNA was obtained from 130 relatives and a further 3 were obligate carriers. 
Fig 3 illustrates the sibships enrolled in the study by carrier status. 
Dr. Elizabeth Dicks and Michael Webb organized research clinics in the community of 
each family. Standardized histories, physical examinations and blood pressure were 
undertaken by Dr. Dicks or Mr. Webb. Physical test performed by the team entailed 
height and weight measurements, blood taken for serum creatinine, blood urea, blood 
sugar and Hemoglobin A1C, and DNA extraction. 
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Figure 2: Ascertainment of BBS Family Members: 
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Figure 3: BBS Family Pedigrees: 
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2.3 Participant Assessment 
Blood Pressure was taken in both a sitting and standing position, and the left arm was 
used for every measure. Blood pressure was measured at least twice in each position. 
Care was taken to ensure that the same arm was used for every study subject where 
possible. A standard blood pressure cuff and stethoscope were used to assess blood 
pressure. Patients were seated comfortably for an extended period prior to blood pressure 
measures being taken. 
Several questions regarding blood pressure were asked in the history assessment. 
Patients were asked to recall if they had ever been diagnosed with hypertension. 
Participants were also asked if they were currently taking any medications to control 
blood pressure, and if they answered in the affirmative, the age they had begun therapy. 
Measurements of height in centimeters, and weight in kilograms were taken using a 
standard tape measure, and a calibrated scale respectively. The height and weight 
measures were used to calculate a body mass index. 
Serum creatinine assessed in the clinical laboratory ofthe Health Sciences Centre was 
used to calculate glomerular filtration rate using the MDRD (modification of diet in renal 
disease) equation. This estimate is reliable and valid [68, 69]. 
The Hemoglobin A 1 c test was also measured in the clinical laboratory of the Health 
Sciences Centre. Patients were asked if they had been diagnosed with diabetes. If so, 
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they were asked to recall at what age they had been told this, what kind of medication, if 
any, they were taking and at what age they had started treatment. 
2.4 Mutation detection 
A collaborative novel gene discovery program was undertaken between 1995 and 2004 
[70,71,72] which lead to the discovery ofBBS6 (34], BBS5 (47] and BBS3 genes (73] . 
In addition mutations causing BBSl, and BBS2 were identified [72, 74]. Following the 
discovery ofBBSlO, the remaining 4 Newfoundland families ofunknown genetic 
etiology were confirmed in France to have mutations in BBS 10. (Personal 
communication: Dr. H. Dollfus). 
DNA was extracted from whole blood by a standard salting out method. DNA was 
amplified by the polymerase chain reaction (PCR) method and electrophoresis was 
performed. The PCR product was then purified. For all BBS genes except BBS3 cycle 
sequencing was undertaken, and sequencing products were precipitated. Sequencing was 
performed using the capillary based ABI 3130 XL. The resultant sequences were 
analysed using the Mutation Surveyor v3.2 program. To determine carrier status in the 
BBS3 family, a restriction enzyme assay was performed. (NEB cutter, V2.0 from New 
England Biolabs. http://tools.neb.com/NEBcutter2/index.php ). 
In 2004, the DNA from 130 family members and from 25 BBS cases was analyzed for 
the 9 different mutations present in Newfoundland BBS families. The mutations are as 
follows: BBSl: M390R; BBS2: Y24X; BBS3: G169A; BBS5 : 1VS6+3A>G; BBS6: 
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F94fs X103, D143fs X157 and L227P; BBSIO: C91fsX95 and, F198del, F199del. Three 
family members were obligate carriers. Of 1170 mutation analyses that were performed 
on relatives ofBBS patients, 5 (0.48%) did not provide a conclusive result. Four carriers 
of a BBS mutation had these 5 inconclusive results. None of these 5 inconclusive 
analyses were for the mutation that was present in the relatives' family. Of225 tests in 
25 cases there were 4 (1.8%) inconclusive analyses. 
2.5 Ethics: 
The Human Investigation Committee (HIC) ofthe Faculty of Medicine, Memorial 
University ofNewfoundland and Labrador approved this research project on April28, 
2004. 
Assessment of the cases was approved by the Memorial University Human Investigation 
Committee and the Simon Fraser University Research Ethics Board prior to the 
investigations of Moore et al. [9] 
2.6 Norms and Definitions: 
The definitions used in this study are the same as those used in the report of Moore et al., 
2005. 
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2.6.1 BBS: 
Presence of at least four of the cardinal features (retinal dystrophy, obesity, renal 
abnormalities, male hypogenitalism, dystrophic extremities) or three cardinal 
manifestations in a sibling of an affected person with four cardinal features [1 0]. 
2.6.2 Obesity: 
A body mass index, calculated from the height and weight measurements taken in the 
physical exam, of 30 or greater kg/m2 [75] 
2.6.3 Hypertension: 
Hypertension was defined as sitting systolic blood pressure of greater than or equal to 
140mm of Hg or a diastolic blood pressure of greater than or equal to 90mm of Hg in 
patients not taking antihypertensive drugs, or being on antihypertensive medications. 
2.6.4 Chronic Renal Impairment/ End Stage Renal Disease: 
Chronic renal failure stages was defined as an estimated creatinine clearance <60 mVmin 
using the MDRD formula [68, 69]. Patients were considered as being End Stage Renal 
Disease if they were on dialysis, or had received a kidney transplant. 
2.6.5 Diabetes mellitus: 
Patients were considered to be diabetic if they were currently undertaking hypoglycemic 
therapy (diet/oral medication/insulin) for diabetes mellitus, had met diagnostic criteria of 
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the 1998 clinical practice guidelines for the management of diabetes in Canada [76] or 
had a hemoglobin A 1 c above 6%. 
2.6.6 Age of onset: 
The age of onset of hypertension, diabetes mellitus, or renal failure was considered to be 
the age at which the clinical end-point was first recorded in the medical history, or when 
diagnostic tests indicated that they were hypertensive, diabetic, or in renal failure. 
2.7 Analysis: 
Mean BMI and blood pressure in carriers and non-carriers were compared using the two-
tailed Student's t-test. Cumulative probability of having an event over time was 
calculated using Kaplan Meier Analysis in cases, carriers and non-carriers. Cox 
regression was performed for each clinical endpoint to assess the hazard in a) cases with 
BBS compared to non-carriers, (b) carriers of a BBS mutation compared to non-carriers. 
The exponent of Beta coefficient and 95% confidence intervals were calculated. 
Statistical significance wasP value< 0.05 . The denominator used in the calculation of 
proportions for clinical endpoints varied, depending on the number of people available 
for testing. Statistical analysis was performed on SPSS, by Michael Webb. 
41 
,------- ----------- - ------------- -
3 
3.1 
Results: 
Cases of BBS: 
Forty-six cases from 26 families were identified. Of 153 siblings 30% had BBS. DNA 
was obtained from members of21 families, and the molecular genetic cause ofthe 
disease was identified in all of these families (Table 1). Nine mutations in 6 BBS genes 
were identified. 
Four BBS 1 families, homozygous for the M390R mutation, clustered on the southwest 
coast (Fig 3). Cases from four BBS6 families, homozygous for the F94fsX103 mutation, 
were from the same bay (Conception Bay). However cases from 2 BBS6 families 
homozygous for D143fsX157 mutations were from distinct regions. Two BBS10 
families, homozygous for C91fsx95, were from communities geographically distant from 
each other (Seal Cove and Green Bay). Individual families with homozygous mutations 
in BBS2, BBS3 and BBS5, and compound heterozygotes of BBS6 and BBS 10 were 
distributed randomly around the coast of the island. 
One of9 BBSl cases was a heterozygous carrier ofthe BBS3 mutation. One of the 15 
BBS6 cases was a heterozygous carrier of the BBS 1 mutation. One of the BBS3 cases 
was a heterozygous carrier ofthe BBS1 mutation. 
At death or last follow up, the cases were younger (40.8 years of age) than carriers (53.8 
years) and non carriers (56.8 years). Fifty seven per cent of cases were male, as were 
43% of carriers, and 46% of non carriers. Of 96 carriers of a BBS mutation BBS 1 
accounted for 47%, BBS2 for 7%, BBS 3 for 2%, BBS 5 for 14%, BBS 6 (through its 3 
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different mutations) for 25%, and BBS 10 for 5% (Table 1). In one BBS1 family (NF-
B 1 0) 3 members carried both a BBS 1 and BBS3 mutation, none of whom presented with 
any ofthe cardinal manifestations ofBBS. These carriers were categorized according to 
the homozygous mutation seen in the BBS cases present in their family (BBS 1) (Table 
2). 
3.2 Body Mass Index 
The body mass index in adults with BBS was significantly higher than that of non 
carriers (38±12 v 29±3). (<.0001) The mean BMI of carriers and non carriers were 
similar (28±6 v 29±3). When analyzed by genotype no differences were observed in 
either the cases or carriers (Table 1 0). 
3.3 Hypertension 
In cases, 33 of 46 (72%) were diagnosed with hypertension, all of whom were treated 
with antihypertensive medication. The median age to onset of hypertension treatment 
was 34 years (95% CI = 31-38) (Table 4). Compared to non carriers, cases were 7 times 
more likely to develop hypertension (Table 4). 
In carriers, 52 of96 (54%) were diagnosed with hypertension, of whom 40 (77%) 
received antihypertensive medication. The median age to hypertension diagnosis in 
carriers was 57 years (95% CI = 54-61) (Table 4) and median age to hypertension 
treatment was 63 years (58-68 years) (Table 5). 
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In non carriers, 17 of35 (49%) were diagnosed with hypertension, 15 (82%) of whom 
were treated. The median age to hypertension diagnosis in non carriers was 67 years 
(95% CI = 59-72) (Table 4) and age to hypertension treatment was 67 years (95% CI = 
59-75). (Table 5) No significant difference in the incidence of hypertension between the 
carriers and non carriers was observed. (Figs. 5&6) 
The mean systolic blood pressure in untreated carriers was 124± 14 mm Hg and in non 
carriers 119± 11 mm Hg respectively. The mean diastolic blood pressure in carriers and 
non carriers was 79±8 mm Hg and 77±8 mm Hg respectively. 
No differences in the incidence of hypertension or treated hypertension were observed 
when carriers were analyzed by genotype (Table 1 0). 
3.4 Diabetes Mellitus 
In cases, 23/46 (50%) had been diagnosed with diabetes mellitus, all of whom were 
treated by insulin, oral hypoglycemic agents or diet. The median age of diagnosis of 
/ 
diabetes was 43 years (95% CI 39-48). There was an 18 fold increased risk of diabetes in 
cases compared to non carriers (Table 6). 
No significant difference was observed in the incidence of diabetes comparing carriers 
and non carriers (Fig 7). In carriers 16/93 (17%) were diagnosed with diabetes, ofwhom 
12 (75%) were receiving treatment. The median age to onset of diabetes mellitus in the 
carriers was 75 years. In non carriers 8/34 (24%) were diagnosed with diabetes mellitus, 
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of whom 7 (88%) were receiving diabetes treatment. By age 70, 45% of non carriers had 
developed diabetes. (Table 6) 
There was no difference in the incidence of diabetes in carriers of a BBS mutation, when 
classified by genotype (Table 1 0). 
3.5 Chronic Renal Failure: 
In cases ofBBS, 20/43 (47%) developed chronic renal failure stage 3. Median age to 
onset of CKD stage 3 was 58 years (95% CI 53-64) (Table 7). There was a 15 fold 
increased risk of CKD in cases compared to non-carriers (Table 7). 
Six cases ofBBS developed end-stage renal disease. By age 60 years 13% ofthe 
population had developed end-stage disease. (Figure 9) 
No significant difference in the incidence of stage 3 CKD comparing carriers and non 
carriers was observed (Fig. 8). In carriers 8/76 (11 %) were diagnosed with stage 3 CKD. 
The median age of onset of chronic renal failure was 86 years (95% CI 81-91) (Table 7). 
In non carriers 5/33 (15%) were diagnosed with stage 3 CKD, with median age to onset 
being 81 years (95% CI 63-99). (Table 7) 
When analyzed by genotype, no differences in the incidence of chronic kidney disease in 
carriers were found. (Table 1 0) 
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3.6 First Renal or Metabolic Illness 
There was no significant difference in incidence between the carriers of BBS and the non 
carriers for at least one of the renal or metabolic outcomes that they were tested for. 
However, there is an 11 fold hazard of composite renal and metabolic illness in BBS 
cases versus non carriers (Table 8). 
In 55/96 (57%) of carriers there was at least one renal or metabolic illness diagnosed. 
The median age ofthe first diagnosis in composite illness was 57 years (95% C.l. 53-61) 
(Table 8). 
Non carriers also had a large proportion ofparticipants, 19/37 (51%), with a diagnosis of 
at least one renal or metabolic illness. The median age of the first diagnosis of renal or 
metabolic illness in this group was 64 years (95% C.l. 58-70) (Table 8). 
Thirty-nine of forty-six (85%) BBS cases had a diagnosis of at least one renal or 
metabolic illness. The median age of the first diagnosis of renal or metabolic illness in 
the cases was 32 years (95% CI 30-34) (Table 8). 
When analyzed by genotype, no differences were observed in either the cases or the 
carriers. 
3.7 Survival in BBS: 
Twelve BBS cases died, with median survival being 63 years (95% CI=62-64). 
Cumulative mortality at age 40 was 12%, at age 50 it was 20% and at age 60 it was 25% 
(Fig. 11 & Table 9). 
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Table 1: BBS Families in Newfoundland by Genotypes 
Mutation Family Cases Carriers Non Carrier 
Identification n=46 n=96 of familial 
mutation 
n=37 
BBS1: M390R B7, B8, B10, 8 45 18 
Bl5, Bl9, Homozygous 
B23 
BBS2: Y24X B14 1 7 2 
Homozygous 
BBS3: G169A B2 5 2 1 
Homozygous 
BBSS: IVS6+3A>G B9 5 13 6 
Homozygous 
BBS6: D143fsX157 B13, B20 4 5 3 
Homozygous 
BBS6: F94fsX 103 B3, B4, B16, 8 13 5 
B25 Homozygous 
BBS6: D143fsX157 B1 2 3 1 
I F94fsX103 Compound 
Heterozygous 
BBS6: F94fsX103 B5 1 3 1 
L227P Compound 
Heterozygous 
BBS10: C91fsX95 B21 , Bl2 4 5 0 
Homozygous 
BBS10: F198 del/ B6, B11 2 0 0 
F199 del/ C91fsX95 Compound 
Heterozygous 
Unknown/No DNA B17, B18, 6 0 0 
B22, B24, 
B26 
Total 26 46 96 37 
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Figure 4: Geographic Distribution of BBS in Newfoundland: 
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Table 2: Additional BBS Mutations That Do Not Match Family Genotype: 
Family Mutation BBS Mutations observed in 
Identification Seen in Relative of BBS Case 
family Case 
B10 BBS1 BBS 1 and 3 
B10 BBS1 BBS 1 and 3 
B10 BBS1 BBS 1 and 3 
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3.8 Analysis of Clinical Outcomes in Cases, Carriers and Non Carriers 
T bl 3 M d Cl' . V . bl . N ~ dl d S b. t a e . easure IDIC ana es m ew oun an U ljeC S . 
Cases Carriers Non Carriers 
Mean I <S.D.> Mean I <S.D.> Mean I <S.D.> 
Freq. I (%) Freq. I (%) Freq. I (%) 
Height (m) n=38 n=75 n=30 
Adults age~ 18 1.63 I <0.10> 1.67 I <0.08> 1.68 I <0.09> 
Mass (kg) n=39 n=73 n=30 
Adults age > 18 99.4 I <31.2> 79.4 I <17.6> 81.4 I <12.9> 
Adult (~18) Body Mass n=38 n=73 n=30 
Index (kglm2) 37.8 I <11.7> 28.4 I <5.6> 28.7 I <2.6> 
30-35 kglm2 n=30 n=15 n=12 
~35 kglm2 n=16 n=6 n=O 
Hypertensive Subjects 33146 (72%) 52196 (54%) 17/35 (49%) 
Prescribed Medication 33133 (100%) 40/52 (77%) 15/17 (82%) 
Hypertensive in Clinic 0134 (0%) 12152 (23%) 2117 (18%) 
Subjects with Chronic 20143 (47%) 8176 (11%) 5133 (15%) 
Renal Failure 
Diabetic Subjects 23146 (50%) 16193 (17%) 8134 {24%) 
Prescribed Medication 23123(100%) 12116 (75%) 7/8 (88%) 
Diabetic in Clinic 0/23 (0%) 4116 (25%) 1/8 (12%) 
Subjects with 39/46 (85%) 55196 (57%) 19137 (51%) 
Diagnosis of Renal or 
Metabolic Illness 
Systolic B.P. n=43 n=l7 
(Normotensive or no 
previous Hypertension 123.7 I <13. 7> 119.4 I <11.4> 
Diagnosis/Unmedicated NIA 
Subjects) mm Hg 
Diastolic B.P. n=43 n=l7 
(Normotensive or no NIA 
previous Hypertension 78.6 I <8.2> 76.5 I <7.9> 
Diagnosis/U nmedicated 
Subjects) mm Hg 
n= subjects for which there was available clinical data for the indicated examination. 
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Figure 5: Time to Hypertension in Cases, Carriers and non Carriers of 
Newfoundland BBS mutations: 
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Figure 6: Time to Treated Hypertension in Cases, Carriers and non Carriers of 
Newfoundland BBS mutations: 
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Table 4: Cumulative Events and Hazard Ratios for Hypertension comparing Cases, 
Carriers and non Carriers of Newfoundland BBS mutations: 
!Mutation Events ~urn. Cum. ~urn. Cum. ~urn. Mean Median IHazard 
!Presence !Events Events !Events Events !Events Age of Age of !Ratio 
~t30 at 40 at so at 60 ~t 70 Event Event 1<95% CI> 
<95%CI> 
Carrier 52 ~.7% 13.7% 33.4% 56.4% 76.3% ~8.9 57 1.45 
(n=96) <53.5- 1<0.84-
60.5> ~.53> 
Non 17 2.8% ~.8% 22.6% ~6.9% 56.0% ~3.8 67 
Carrier <58.7-
(n=35) 72.3> 
Case 33 30.7% ~2.1% 84% ~4.7% 94.7% ~5.3 34 7.34 
(n=46) <30.5- <3.93-
37.5> 13.71> 
Table 5: Cumulative Events and Hazard Ratios for Treated Hypertension 
Comparing Cases, Carriers and non Carriers of Newfoundland BBS mutations: 
Mutation Events K:um. Cum. Cum. Cum. ~urn. Mean Median Hazard 
Presence !Events Events Events Events !Events Age of Age of Ratio 
Fit 30 at 40 at 50 at 60 nt 70 Event Event <95% 
<95% CI> Cl> 
Carrier 40 5.6% 14.5% 25% 46.2% 66.2% ~2.6 63 1.24 
(n=96) <58.3- <0.68-
67.7> 2.25> 
Non 15 2.8% 5.8% 25.6% ~6.9% 56% ~4.6 67 
Carrier <58.7-
(n=35) 75.3> 
Case 33 30.7% 72.1% 84% ~4.7% 94.7% ~5.3 34 7.76 
(n=46) <30.5- <4.05-
37.5> 14.9> 
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Figure 7: Time to Diabetes Mellitus in Cases, Carriers and non Carriers 
of Newfoundland BBS mutations: 
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Table 6: Cumulative Events and Hazard Ratios for Diabetes Mellitus comparing 
Cases, Carriers and non Carriers ofNewfoundland BBS mutations: 
Mutation Events K:um. ~urn. K:um. Cum. Cum. Mean Median Hazard 
Presence fEvents Events fEvents Events Events age of age of Ratio 
~t 30 at 40 ~t 50 at 60 at 70 Event Event <95% CI> 
<95% 
CI> 
Carrier 16 0 1.2% 2.9% 9.0% 23.4% 76.2 75 0.71 
(n=93) <73.3- <0.30-
76.7> 1.70> 
Non 8 0 0 7.1% 20.7 45.1 % 72.7 
Carrier % <nla> 
(n=34) 
Case 23 15.1 36.7 63.1 100 100% 44.0 43 18.16 
(n=46) % % % % <38.5- <6.84-
47.5> 48.18> 
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Figure 8: Time to Chronic Renal Failure in Cases, Carriers and non Carriers of 
Newfoundland BBS mutations: 
1.0 ..j,. 
.;-;;. "1 ttl 
'* 
-
.... , 
i-t~t 
0.8 
·l.+ II 
"l l ~ Carrier 
-tiS 
.~ ..., 
~ 0.6 r Non Ca-rri~r ? :::s 
(/) 
11 Q) ~ LL 
Q) 0.4 l en tiS Q) t/) 
·-c 
0.2 
Case ~ 
'l 
0.0 I 
0 20 40 GO 80 100 
Age at Chronic Renal Failure or Last Follow up 
56 
Table 7: Cumulative Events and Hazard Ratios for Chronic Renal Failure 
comparing Cases, Carriers and non Carriers of Newfoundland BBS mutations: 
Mutation Events ~urn. Cum. ~urn. Cum. ~urn. Mean Median Hazard 
Presence ~vents Events ~vents Events ~vents age of age of Ratio 
~t 30 at 40 ~t 50 at 60 ~t 70 Event Event <95%-
<95% CI> 
Cl> 
Carrier 8 0 0 0 3.9% 4.5% 82.8 86 0.59 
(n=76) <81.4- <0.19-
90.6> 1.19> 
Non 5 0 0 0 4.5% ~.1.2% 76.9 81 
Carrier <62.6-
(n=33) 99.4> 
Case 20 5% 16.3% 20% ~9.6% 00% 54.7 58 15.06 
(n=43) <52.5- <5.06-
63.5> 44.84> 
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Figure 9: Time to End Stage Renal Disease in Cases of BBS: 
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Figure 10: Time to Composite Renal and Metabolic Illness in Cases, Carriers and 
non Carriers ofNewfoundland BBS mutations: 
1.0 
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Table 8: Cumulative Events and Hazard Ratios for Composite Renal and Metabolic 
Ill . C . d C . f N ~ dl d BBS t f ness com parmg arners an non arners o ew oun an mu a 1ons: 
Mutation !Events Cum. ~urn. K::um. Cum. ~urn. Mean Median Hazard 
Presence Events IE vents !Events Events !Events age of age of Ratio 
at 30 ~t 40 ~t 50 at 60 ~t 70 Event Event <95%CI> 
1<95% Cl> 
Carrier 55 6 .7% 15.1 % 33.4% 56.3% 79.1 % 58 57 1.38 
(n=96) <53 .1 - <0.81-
60.9> 2.33> 
Non 19 2.8% 8.6% 21.7% 38.6% 50.8% 60 64 
Carrier <58.1-
(n=37) 69.9> 
Case 39 31. 70f< 83.3% 93.5% 100% 100% 31.2 32 11.33 
(n=46) <30.2- <6.11-
33.8> 21.0> 
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Figure 11: Time to Death in Cases ofBBS: 
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T able 9: Mortalit yin Cases ofNewfoundland BBS 
Events Cum. Cum. Cum. Cum. Cum. Mean Median 
Events Events Events Events Events age of age of 
at 30 at 40 at 50 at 60 at 70 Event Event 
<95% 
CI> 
Case 12 6.8% 12.3% 20% 25.3% 100% 58.6 63 
n=46 <61.6-
64.4> 
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3.9: Genotype Analysis of Carriers and Cases: 
Table 10: Renal and Metabolic Event Rate in Carriers and Cases by Genotype 
All other BBS Unknown 
BBS 1 BBS5 BBS6 Genotype Mutation 
Measure 
In Clinic 
Distribution 45 ~ 13 ~ 24 15 14 12 ~Cases 
in Carriers/ 
Cases 
Mean/S.D. iMean/S.D. iMean/S.D. iMean/S.D. Mean/S.D 
Adult Body n=38 r =7 r =12 n=5 r = 12 n=10 r = 11 r =4 h=5 
Mass Index 29.11 p6.51 ~7 .5 I 46.1/ ~7 . 8 I 39.51 ~8 . 1 I ps.u 33.61 
(kg/m2) <5.4> 1<3.4> 1<4.2> <17.4> ~.6> <17.0> 1<9.5> 1<6.6> <6.2> 
Subjects with n=34 n/a n=8 n/a n=12 r;a n=7 r;a n/a 
Untreated 5.4 1 5.4 / 5.2 I 5.2 I 
Diabetes or no 1<0.4> <0.6> <0.6> <0.5> 
diagnosis of 
diabetes 
HbAIC (%) 
Diabetes by r =3/42 n=418 n=3113 r =21s n=2/24 r =711s n= l/14 r =7112 n=3/6 
age 70 7% ~0% 23% ~0% 8% ~7% ~% 58% ~0% 
Hypertension n=27/ r =718 n=5113 r =41s r =9124 n= I0/15 ]=8/14 n=8/12 r =416 
by age 70 45 ~8% 38% ~0% p7.5% 67% ~7% 67% ~7% 
60% 
Chronic Renal 3/43 ~18 1113 ~15 1119 5/14 PI It 5/12 ~16 
Failure by age 
70 7% ~5% ~% ~0% ~% 36% p% 42% ~7% 
Systolic B.P. n=22 r,ta r =7 n/a r =s n/a r =6 n/a r,ta 
(Normotensive 127.01 123.41 118.51 119.0 
and <13.7> 1<18.1> 1<9.6> 12.5> 
Unmedicated 
Subjects) mm 
Hg 
Diastolic B.P. n=22 n/a r =7 n/a r =s rva n=6 rva n/a 
(Normotensive 81.31 ~7.7 I ~4.5/ 75.0 
and <8.7> 1<4.7> 1<10.6> <7.8> 
Unmedicated 
subjects) mm 
Hg 
n= number of subjects for which there was available clinical data for the indicated 
examination 
!comparison 
~mongst 
penotype: 
p= 
~ar. lease 
812 .407 
542 
.390 
.174 
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4.1 
Discussion 
Genetic Epidemiology ofBBS in a Large Population: 
BBS is caused by mutations in multiple different genes. The biologic complexities of the 
cilium/basal body/centrosome, which is dependent on multiple genes [ 48] implies that 
many pathogenic BBS mutations may occur. It is likely that some of the approximately 
30,000 founders of the Newfoundland population carried different heterozygous BBS 
mutations to Newfoundland 8 to 10 generations ago. Their progeny experienced 
geographic and religious isolation which predisposed to occurrence of affected 
individuals with this autosomal recessive condition. In fact, 9 different BBS mutations 
and one variant have been discovered in the Newfoundland population. Several families 
with the same BBS 1 or BBS6 homozygous mutations were clustered in specific genetic 
isolates. Individual families with homozygous mutations of different genes and other 
families with BBS caused by compound heterozygote mutations have been identified in 
random locations around the island. Thus it appears that the genetic complexity of the 
cilium/basal body/centrosome leading to multiple mutations, founder effects and the high 
inbreeding coefficient in multiple Newfoundland isolates, has caused the high incidence 
of autosomal recessive BBS in Newfoundland. 
It is likely that BBS heterozygotes occur in the general population. In the region where 
BBS 1 families are most common (South-West Newfoundland) 6 BBSJ carriers were 
identified in a group of 400 control individuals studied (1.5%) [27]. In the current study 
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additional BBS mutations were identified in 3 of 130 (2.3%) relatives that differed from 
the mutations causing BBS in their families. 
4.2 Renal and Metabolic Illness: 
This study clearly demonstrates that early onset obesity, hypertension, diabetes mellitus, 
chronic kidney disease and early death are associated with BBS. It is possible that the 
high incidence of genetically complex manifestations, such as hypertension and diabetes, 
in the BBS cases was influenced by other genetic influences prevalent in the population. 
The non carriers certainly had a high incidence of hypertension, but obesity was less 
prevalent than in cases and the onset of hypertension, diabetes and chronic renal disease 
was of substantially later onset. 
4.2.1 Renal Events: 
It is likely that primary ciliary dysfunction in BBS predisposes to the renal and endocrine 
events reported here. In normal kidneys the epithelial cilia are sensory transducers in a 
cilium-generated signaling pathway [57]. Abnormal ciliary function leads to cysts, 
calyceal clubbing and tubular defects [16, 44, 46]. Defective expression of BBS proteins 
could also lead to permanent changes in cellular properties that lead to early onset kidney 
dysfunction [ 44]. 
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4.2.2 Pancreatic and Diabetic Events: 
Cilia have been identified in the exocrine, endocrine and ductal cells of the pancreas for 
many years [ 44]. Ciliary defects have been associated with acinar cell atrophy and duct 
hyperplasia, and compromised glucose homeostasis. BBS patients are prone to type 2 
diabetes and have high insulin levels [4], suggesting that both obesity and primary 
pancreatic disease contribute to insulin resistance. Alstrom's Syndrome is another 
autosomal recessive ciliopathy strongly associated with diabetes and insulin resistance 
[59]. 
4.2.3 Obesity: 
It is not fully understood how defective cilia predispose to obesity. Neuronal cilia-
dwelling receptors could be involved in regulating food intake and overall energy 
metabolism. In fact, many neurons that are responsive to the weight regulating protein 
leptin display somatostatin 3 receptors on their cilia [61]. Consequently dysfunctional 
cilia associated with BBS could predispose to dysregulation of energy metabolism. Type 
II chaperonin proteins ensure proper folding of proteins. BBS6, 10 and 12 genes code for 
proteins with similar properties to chaperonins [19, 34, 44, 77] , and mutations in these 
genes may result in abnormal proteins, which could possibly be responsible for improper 
folding of leptin, and thus predispose to the development of obesity. In addition cilia 
have been observed in the fat storing cells of the liver, in the thyroid and in the adrenal 
glands, defects in which could lead to defective storage of fat, and abnormalities in 
thermoregulation and metabolic rate [44]. 
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4.2.4 Hypertension: 
The etiology of hypertension in BBS is likely to be complex. Predisposing factors 
include primary renal disease, diabetes mellitus and obesity which occur frequently in 
BBS. Furthermore abnormalities in intracellular calcium signaling in vascular cells may 
induce dysregulation of contraction and predispose to hypertension [58]. In addition an 
underlying genetic predisposition to hypertension may cluster in these families. 
4.3 Phenotype/Genotype Comparisons: 
The fact that nine different mutations in six different BBS genes are associated with a 
similar phenotype suggests that all of the BBS genes are necessary for later organ 
differentiation. The cilium/basal body/centrosome structure appears to be critical in the 
proper development of kidneys, liver, pancreas, and other endocrine organs as renal and 
metabolic illness arising from these systems are seen in all BBS genotypes. 
The heterozygote state is not associated with a predisposition to endocrine and renal 
events associated with BBS, as the prevalence of obesity and incidence of hypertension, 
diabetes and chronic kidney disease are comparable in BBS mutation carriers compared 
to non carriers. The observation of similar BMI in BBS mutation carriers and non-
carriers is consistent with our results from a study of BBS 1 genotype in obesity, in the 
geographic area where cases caused by BBSJ mutations were identified [27]. The BBSJ 
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mutation was found in the heterozygous state in 3 of 200 obese individuals and also in 3 
of 200 matched non obese controls. 
4.4 Study Limitations: 
The limitations of this study include small numbers enrolled in the study, potential 
ascertainment bias, and definitions of clinical manifestations which may provide higher 
estimates of disease. However this is a population based study likely to have identified 
most of the cases who presented with blindness, a clinical manifestation highly prevalent 
in BBS. The definitions of disease are less likely to be a problem in the cases who we 
have been following for 28 years, but may be less reliable in relatives who have been 
assessed once. The virtual overlap of time-to-event curves suggests that very large 
numbers of relatives would be required to disprove our conclusion that endocrine/renal 
events are similar in carriers and non carriers. 
4.5 Summary 
The high prevalence ofBBS in Newfoundland is likely the result of the inbreeding 
coefficient in multiple genetic isolates and the frequency of pathogenic BBS mutations in 
founders. BBS includes early onset obesity, hypertension, diabetes mellitus, and chronic 
kidney disease, which may be associated with ciliary dysfunction in a variety of organs. 
The incidence of renal and metabolic diseases was similar in carriers and non carriers of 
the Newfoundland BBS mutations. No statistically significant variation between either 
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carriers or non carriers was found in any of the outcomes sought in this study. The 
heterozygote BBS state is not associated with increased risk for these endocrine and renal 
events in this population. 
69 
References: 
1. Parfrey PS, Davidson WS, Green JS: Clinical and genetic epidemiology of 
inherited renal disease in Newfoundland. Kidney Int, 61:1925-34, 2002. 
2. Bear JC, Nemec TF, Kennedy JC, Marshall WH, Power AA, Kolonel VM, Burke 
GB: Persistent genetic isolation in outport Newfoundland. Am J Med Genet, 
27:807-30, 1987. 
3. ServiceS, DeYoung J, Karayiorgou M, Roos JL, Pretorious H, Bedoya G, Ospina 
J, Ruiz-Linares A, Macedo A, Palha JA, Heutink P, Aulchenko Y, Oostra B, van 
Duijn C, Jarvelin MR, Varilo T, Peddle L, Rahman P, Piras G, Monne M, Murray 
S, Galver L, Peltonen L, Sabatti C, Collins A, Freimer N: Magnitude and 
distribution of linkage disequilibrium in population isolates and implications for 
genome-wide association studies. Nat Genet, 38:556-60, 2006. 
4. Green JS, Parfrey PS, Harnett JD, Farid NR, Cramer BC, Johnson G, Heath 0 , 
McManamon PJ, O'Leary E, Pryse-Phillips W: The cardinal manifestations of 
Bardet-Biedl syndrome, a form ofLaurence-Moon-Biedl syndrome. N Engl J 
Med, 321:1002-9, 1989. 
5. Ammann F, Klein D, Prader A, Hauser A: [Two big genealogical trees with 
Bardet-Biedl syndrome from central Switzerland. Contribution to the study of 
isolates]. Arch Julius Klaus Stift Vererbungsforsch Sozialanthropol Rassenhyg, 
41:67-81, 1967. 
70 
6. Klein D, Ammann F: The syndrome of Laurence-Moon-Bardet-Biedl and allied 
diseases in Switzerland. Clinical, genetic and epidemiological studies. J Neurol 
Sci, 9:479-513, 1969. 
7. Beales PL, Elcioglu N, Woolf AS, Parker D, Flinter FA: New criteria for 
improved diagnosis of Bardet-Biedl syndrome: results of a population survey. J 
Med Genet, 36:437-46, 1999. 
8. Beales PL, Reid HA, Griffiths MH, Maher ER, Flinter FA, Woolf AS: Renal 
cancer and malformations in relatives of patients with Bardet-Biedl syndrome. 
Nephrol Dial Transplant, 15:1977-85,2000. 
9. Moore SJ, Green JS, Fan Y, Bhogal AK, Dicks E, Fernandez BA, Stefanelli M, 
Murphy C, Cramer BC, Dean JC, Beales PL, Katsanis N, Bassett AS, Davidson 
WS, Parfrey PS: Clinical and genetic epidemiology of Bardet-Biedl syndrome in 
Newfoundland: a 22-year prospective, population-based, cohort study. Am J Med 
Genet A, 132:352-60, 2005. 
10. Farag T, Teebi AS: Letters to the Editor: High Incidence of Bardet Biedl 
Syndrome among the Bedouin. Clinical Genetics, 36:463-465, 1989. 
11. Laurence JZ, Moon RC: Four cases of Retinitis Pigmentosa occuring in the same 
family, and accompanied by general imperfections of development. Opthalmol 
Rev, 2:32-41, 1866. 
12. Bardet G: Sur un syndrome d'obesity congenitale avec polydactyly et retinite 
pigmentaire (contribution a !'etude des formes cliniques de !'obesity 
hypophysaire). These de Paris, 470, 1920. 
71 
13. Biedl A: Ein Geschwister mit adiposogenitaler Dystropie. Dtsch Med 
Wochenschr., 48:1630, 1922. 
14. Solis-Cohen S, WeissE: Dystrophia adiposogenitalis, with atypical retinitis 
pigmentosa and mental deficiency- The Laurence-Biedl Syndrome. A report of 
Four Cases in One Family. Am J Med Sci, 169:489-505, 1925. 
15. Schachat AP, Maumenee IH: Bardet-Biedl syndrome and related disorders. Arch 
Ophthalmol, 100:285-8, 1982. 
16. Harnett JD, Green JS, Cramer BC, Johnson G, Chafe L, McManamon P, Farid 
NR, Pryse-Phillips W, Parfrey PS: The spectrum of renal disease in Laurence-
Moon-Biedl syndrome. N Eng/ J Med, 319:615-8, 1988. 
17. Beales PL: Lifting the lid on Pandora's box: the Bardet-Biedl syndrome. Curr 
Opin Genet Dev, 15:315-23, 2005. 
18. O'Dea D, Parfrey PS, Harnett JD, Hefferton D, Cramer BC, Green J: The 
importance of renal impairment in the natural history ofBardet-Biedl syndrome. 
Am J Kidney Dis, 27:776-83, 1996. 
19. Stoetzel C, Muller J, Laurier V, Davis EE, Zaghloul NA, Vicaire S, Jacquelin C, 
Plewniak F, Leitch CC, Sarda P, Hamel C, de Ravel TJ, Lewis RA, Friederich E, 
Thibault C, Danse JM, Verloes A, Bonneau D, Katsanis N, Poch 0 , Mandel JL, 
Dollfus H: Identification of a novel BBS gene (BBS 12) highlights the major role 
of a vertebrate-specific branch of chaperonin-related proteins in Bardet-Biedl 
syndrome. Am J Hum Genet, 80:1-11 , 2007. 
72 
.-----------------------------------------------------------------------
20. Chiang AP, Beck JS, Yen HJ, Tayeh MK, Scheetz TE, Swiderski RE, Nishimura 
DY, Braun TA, Kim KY, Huang J, Elbedour K, Carmi R, Slusarski DC, Casavant 
TL, Stone EM, Sheffield VC: Homozygosity mapping with SNP arrays identifies 
TRIM32, an E3 ubiquitin ligase, as a Bardet-Biedl syndrome gene (BBS11). Proc 
Nat! Acad Sci US A, 103:6287-92, 2006. 
21. Katsanis N: The oligogenic properties ofBardet-Biedl syndrome. Hum Mol 
Genet, 13 Spec No 1 :R65-71 , 2004. 
22. Mykytyn K, Nishimura D, Searby CC, Shastri M, Yen HJ, Beck JS, Braun T, 
Streb LM, Cornier AS, Cox GF, Fulton AB, Carmi R, Luleci G, 
Chandrasekharappa SC, Collins FS, Jacobsen SG, Heckenlively JR, Weleber RG, 
Stone EM, Sheffield VC: Identification of the gene (BBSl) most commonly 
involved in Bardet-Biedl Syndrome, a complex human obesity syndrome. Nat 
Genet, 31:435-438, 2002. 
23. OMIM: Online Mendelian Inheritance in Man. www.ncbi.nlm.nih.gov/Omim. 
24. Ansley S, Badano JL, Blacque OE, Hill J, Hoskins BE, Leitch CC, Kim JC, Ross 
AJ, Eichers ER, Teslovich TM, Mah AK, Johnsen RC, Cavender JC, Lewis RA, 
Leroux MR, Beales PL, Katsanis N: Basal body dysfunction is a likely cause of 
pleiotropic Bardet-Biedl syndrome. Nature, 425:628-33, 2003 . 
25. Nishimura D, Searby CC, Carmi R, Elbedour K, Van Maldergerm L, Fulton AB, 
Lam BL, Powell BR, Swiderski RE, Bugge KE, Haider NB, Kwitek-Black AE, 
Ying L, Duhl DM, Gorman SW, Heon E, Iannaccone A, Bonneau D, Biesecker 
LG, Jacobsen SG, Stone EM, Sheffield VC: Positional Cloning of a novel gene on 
73 
chromasome 16q causing Bardet-Biedl Syndrome. Hum Mol Genet, 10:865-874, 
2001. 
26. Ross AJ, Beales PL: Bardet-Biedl Syndrome. Gene Reviews, www.genetests.org, 
2007. 
27. Fan Y, Rahman P, Peddle L, Hefferton D, Gladney N, Moore SJ, Green JS, 
Parfrey PS, Davidson WS: Bardet-Biedl syndrome 1 genotype and obesity in the 
Newfoundland population. Int JObes Relat Metab Disord, 28:680-4, 2004. 
28. Katsanis N, Eichers ER, Ansley SJ, Lewis RA, Kayserili H, Hoskins BE, 
Scambler PJ, Beales PL, Lupski JR: BBS4 is a minor contributor to Bardet-Biedl 
syndrome and may also participate in triallelic inheritance. Am J Hum Genet, 
71:22-9,2002. 
29. Ross AJ, May-Simera H, Eichers ER, Kai M, Hill J, Jagger DJ, Leitch CC, 
Chapple JP, Munro PM, FisherS, Tan PL, Phillips HM, Leroux MR, Henderson 
DJ, Murdoch JN, Copp AJ, Eliot MM, Lupski JR, Kemp DT, Dollfus H, Tada M, 
Katsanis N, Forge A, Beales PL: Disruption ofBardet-Biedl syndrome ciliary 
proteins perturbs planar cell polarity in vertebrates. Nat Genet, 37:1135-40, 2005. 
30. Mykytyn K, Braun T, Carmi R, Haider NB, Searby CC, Shastri M, Beck G, 
Wright AF, Iannaccone A, Elbedour K, Riise R, Baldi A, Raas-Rothschild A, 
Gorman SW, Duhl DM, Jacobsen SG, Casavant T, Stone EM, Sheffield VC: 
Identification of the gene that, when mutated, causes the human obesity syndrome 
BBS4. Nat Genet, 28:188-191,2001. 
74 
31. Kulaga HM, Leitch CC, Eichers ER, Badano JL, Lesemann A, Hoskins BE, 
Lupski JR, Beales PL, Reed RR, Katsanis N: Loss ofBBS proteins causes 
anosmia in humans and defects in olfactory cilia structure and function in the 
mouse. Nat Genet, 36:994-8, 2004. 
32. Mykytyn K, Mullins RF, Andrews M, Chiang AP, Swiderski RE, Yang B, Braun 
T, Casavant T, Stone EM, Sheffield VC: Bardet-Biedl syndrome type 4 (BBS4)-
null mice implicate Bbs4 in flagella formation but not global cilia assembly. Proc 
Nat! Acad Sci US A, 101:8664-9, 2004. 
33. Kim JC, Ou YY, Badano JL, Esmail MA, Leitch CC, Fiedrich E, Beales PL, 
Archibald JM, Katsanis N, Rattner JB, Leroux MR: MKKS/BBS6, a divergent 
chaperonin-like protein linked to the obesity disorder Bardet-Biedl syndrome, is a 
novel centro somal component required for cytokinesis. J Cell Sci, 118:1007-20, 
2005. 
34. Katsanis N, Beales PL, Woods MO, Lewis RA, Green JS, Parfrey PS, Ansley SJ, 
Davidson WS, Lupski JR: Mutations in MKKS cause obesity, retinal dystrophy 
and renal malformations associated with Bardet-Biedl syndrome. Nat Genet, 
26:67-70, 2000. 
35. Fath MA, Mullins RF, Searby C, Nishimura DY, Wei J, Rahmouni K, Davis RE, 
Tayeh MK, Andrews M, Yang B, Sigmund CD, Stone EM, Sheffield VC: Mkks-
null mice have a phenotype resembling Bardet-Biedl syndrome. Hum Mol Genet, 
14:1109-18,2005. 
75 
36. Blacque OE, Reardon MJ, Li C, McCarthy J, Mahjoub MR, Ansley SJ, Badano 
JL, Mah AK, Beales PL, Davidson WS, Johnsen RC, Audeh M, Plasterk RH, 
Baillie DL, Katsanis N, Quarmby LM, Wicks SR, Leroux MR: Loss of C. elegans 
BBS-7 and BBS-8 protein function results in cilia defects and compromised 
intraflagellar transport. Genes Dev, 18:1630-42, 2004. 
37. Kubo A, Sasaki H, Yuba-Kubo A, Tsukita S, Shiina N: Centriolar satellites: 
molecular characterization, A TP-dependent movement toward centrioles and 
possible involvement in ciliogenesis. JCell Bioi, 147:969-80, 1999. 
38. Yen HJ, Tayeh MK, Mullins RF, Stone EM, Sheffield VC, Slusarski DC: Bardet-
Biedl syndrome genes are important in retrograde intracellular trafficking and 
Kupffer's vesicle cilia function. Hum Mol Genet, 15:667-77, 2006. 
39. Nishimura DY, Swiderski RE, Searby CC, Berg EM, Ferguson AL, Hennekam R, 
Merin S, Weleber RG, Biesecker LG, Stone EM, Sheffield VC: Comparative 
genomics and gene expression analysis identifies BBS9, a new Bardet-Biedl 
syndrome gene. Am J Hum Genet, 77:1021-33, 2005. 
40. Stoetzel C, Laurier V, Davis EE, Muller J, Rix S, Badano JL, Leitch CC, Salem 
N, Chouery E, Corbani S, Jalk N, Vicaire S, Sarda P, Hamel C, Lacombe D, 
Holder M, Odent S, Holder S, Brooks AS, Elcioglu NH, Silva ED, Rossillion B, 
Sigaudy S, de Ravel TJ, Lewis RA, Leheup B, Verloes A, Amati-Bonneau P, 
Megarbane A, Poch 0 , Bonneau D, Beales PL, Mandel JL, Katsanis N, Dollfus 
H: BBS 10 encodes a vertebrate-specific chaperonin-like protein and is a major 
BBS locus. Nat Genet, 38:521-4,2006. 
76 
~~~~~~~~~~~~~~~~~~~~~~~~~- ------ - --
41. Badano JL, Leitch CC, Ansley SJ, May-Simera H, Lawson S, Lewis RA, Beales 
PL, Dietz HC, Fisher S, Katsanis N: Dissection of epistasis in oligogenic Bardet-
Biedl syndrome. Nature, 439:326-30, 2006. 
42. Dollfus H, Verloes A, Bonneau D, Cossee M, Perrin-Schmitt F, Brandt C, 
Flament J, Mandel JL: [Update on Bardet-Biedl syndrome]. J Fr Ophtalmol, 
28:106-12, 2005 . 
43 . Kim JC, Badano JL, Sibold S, Esmail MA, Hill J, Hoskins BE, Leitch CC, 
Venner K, Ansley SJ, Ross AJ, Leroux MR, Katsanis N , Beales PL: The Bardet-
Biedl protein BBS4 targets cargo to the pericentriolar region and is required for 
microtubule anchoring and cell cycle progression. Nat Genet, 36:462-70, 2004. 
44. Pan J, Wang Q, Snell WJ: Cilium-generated signaling and cilia-related disorders. 
Lab Invest, 85:452-63, 2005. 
45. Davenport JR, Yoder BK: An incredible decade for the primary cilium: a look at a 
once-forgotten organelle. Am J Physiol Renal Physiol, 289:Fll59-69, 2005 . 
46. Praetorius HA, Spring KR: A physiological view of the primary cilium. Annu Rev 
Physiol 2004, 2004. 
47. Li JB, Gerdes JM, Haycraft CJ, Fan Y, Teslovich TM, May-Simera H, Li H, 
Blacque OE, Li L, Leitch CC, Lewis RA, Green JS, Parfrey PS, Leroux MR, 
Davidson WS, Beales PL, Guay-Woodford LM, Yoder BK, Stormo GD, Katsanis 
N, Dutcher SK: Comparative genomics identifies a flagellar and basal body 
proteome that includes the BBS5 human disease gene. Cell, 117:541-52, 2004. 
77 
----- -- -------~---"--------------~-- --
48. Mykytyn K, Sheffield VC: Establishing a connection between cilia and Bardet-
Biedl Syndrome. Trends Mol Med, 10:106-9, 2004. 
49. Huangfu D, Liu A, Rakeman AS, Murcia NS, Niswander L, Anderson KV: 
Hedgehog signalling in the mouse requires intraflagellar transport proteins. 
Nature, 426:83-7, 2003 . 
50. WISC:Zoology: Neurulation. 
http://worms.zoology. wise. edu/{rogs/neuru/neurul intra. html. 
51 . Katzmarzyk PT, Janssen 1: The economic costs associated with physical inactivity 
and obesity in Canada: an update. Can J Appl Physiol, 29:90-115, 2004. 
52. Canadian Diabetic Association: The Prevalence and Cost of Diabetes in Canada. 
53. Joffres MR GP, Fodor JG, Petrasovies A, Chockalingham A, Hamet P: 
Awareness, Treatment, and Control of Hypertension in Canada. Am J 
Hyper tens: 1097-1102, 1997. 
54. Kannel W: Blood Pressure as a Cardiovascular Risk Factor. Jama :1571 -1576, 
1996. 
55 . Zelmer JL: The economic burden of end-stage renal disease in Canada. Kidney 
/nt:11 22-1129, 2007. 
56. Davenport JR, Watts AJ, Roper VC, Croyle MJ, van Groen T, Wyss JM, Nagy 
TR, Kesterson RA, Yoder BK: Disruption of intraflagellar transport in adult mice 
leads to obesity and slow-onset cystic kidney disease. Curr Bioi, 17:1586-94, 
2007. 
78 
57. Praetorius HA, Spring KR: The renal cell primary cilium functions as a flow 
sensor. Curr OpinNephrol Hypertens, 12:517-20,2003. 
58. Qian Q, Hunter L W, Li M, Marin-Padilla M, Prakash YS, Somlo S, Harris PC, 
Torres VE, Sieck GC: Pkd2 haploinsufficiency alters intracellular calcium 
regulation in vascular smooth muscle cells. Hum Mol Genet, 12:1875-80, 2003. 
59. Hearn T. SC, Phillips V.J., Renforth G.L., Copin N., Hanley N.A., Wilson D.I.: 
Subcellular Localisation of ALMS 1 Supports Involvement of Centrosome and 
Basal Body Dysfunction in the Pathogenesis of Obesity, Insulin Resistance, and 
Type 2 Diabetes. Diabetes: 1581-1587, 2005. 
60. Praetorius HA, Spring KR: Removal of the MDCK cell primary cilium abolishes 
flow sensing. J Membr Bioi, 191:69-76,2003. 
61. Stepanyan Z, Kocharyan A, Pyrski M, Hubschle T, Watson AM, Schulz S, 
Meyerhof W: Leptin-target neurones ofthe rat hypothalamus express 
somatostatin receptors. J Neuroendocrinol, 15:822-30, 2003. 
62. Hjortshoj T, Gronskov K, Rosenberg T, Brodum-Nielsen K, Olsen JH: Risk for 
Cancer in Patients with Bardet-Biedl Syndrome and the Relatives. Am J Med 
Genet A 143:1699-1702, 2007. 
63 . Swift M, Morrell D, Massey RB, Chase CL: Incidence of cancer in 161 families 
affected by ataxia-telangiectasia. N Eng! J Med, 325:1831-6, 1991. 
64. Croft JB, Morrell D, Chase CL, Swift M: Obesity in heterozygous carriers of the 
gene for the Bardet-Biedl syndrome. Am J Med Genet, 55:12-5, 1995. 
79 
-------------- ------ - ---------
65. Croft JB, Swift M: Obesity, hypertension, and renal disease in relatives ofBardet-
Biedl syndrome sibs. Am J Med Genet, 36:37-42, 1990. 
66. (USA) NCFHS: National Health and Nutrition Examination Survey. 1976-1980. 
67. Hall JG, Froster-Iskenius UG, Allanson JE: Handbook ofNormal Physical 
Measurements. Oxford Medical Publications, 1995. 
68. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate 
method to estimate glomerular filtration rate from serum creatinine: a new 
prediction equation. Modification of Diet in Renal Disease Study Group. Ann 
Intern Med, 130:461-70, 1999. 
69. Stevens LA, Coresh J, Feldman HI, Greene T, Lash JP, Nelson RG, Rahman M, 
Deysher AE, Zhang YL, Schmid CH, Levey AS: Evaluation of the modification 
of diet in renal disease study equation in a large diverse population. JAm Soc 
Nephrol, 18:2749-57, 2007. 
70. Woods MO, Young TL, Parfrey PS, Hefferton D, Green JS, Davidson WS: 
Genetic heterogeneity of Bardet-Biedl syndrome in a distinct Canadian 
population: evidence for a fifth locus. Genomics, 55:2-9, 1999. 
71. Young TL, Woods MO, Parfrey PS, Green JS, O'Leary E, Hefferton D, Davidson 
WS: Canadian Bardet-Biedl syndrome family reduces the critical region ofBBS3 
(3p) and presents with a variable phenotype. Am J Med Genet, 78:461-7, 1998. 
72. Young TL, Woods MO, Parfrey PS, Green JS, Hefferton D, Davidson WS: A 
founder effect in the Newfoundland population reduces the Bardet-Biedl 
syndrome I (BBS1) interval to 1 eM. Am J Hum Genet, 65:1680-7, 1999. 
80 
73. Fan Y, Esmail MA, Ansley SJ, Blacque OE, Boroevich K, Ross AJ, Moore SJ, 
Badano JL, May-Simera H, Compton DS, Green JS, Lewis RA, Van Haelst MM, 
Parfrey PS, Baillie DL, Beales PL, Katsanis N, Davidson WS, Leroux MR: 
Mutations in a Member of the RAS Super Family of small GTP-Binding Proteins 
causes Bardet-Biedl Syndrome. Nat. Genet, 36:989-93, 2004. 
74. Fan Y, Green JS, Ross AJ, Beales PL, Parfrey PS, Davidson WS: Linkage 
disequilibrium mapping in the Newfoundland population: a re-evaluation of the 
refinement of the Bardet-Biedl syndrome I critical interval. Hum Genet, 116:62-
71 , 2005. 
75 . Twells L: Obesity and its Impact on a Provincial Health System. PhD 
Dissertation, Memorial University, 2008. 
76. Meltzer S, Leiter L, Daneman D, Gerstein HC, LauD, Ludwig S, Yale JF, 
Zinman B, Lillie D: 1998 clinical practice guidelines for the management of 
diabetes in Canada. Canadian Diabetes Association. Cmaj, 159 Suppl 8:Sl-29, 
1998. 
77. Slavotinek A, Stone EM, Mykytyn K, Heckenlively JR, Green JS, Heon E, 
Musarella MA, Parfrey PS, Sheffield VC, Biesecker LG: Mutations in MKKS 
cause Bardet Biedl Syndrome. Nat Genet, 26:15-16, 2000. 
81 




